Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics: Panic Creates Opportunity
08:52pm, Wednesday, 20'th Aug 2025
Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstr
Here's Why Viking Therapeutics Bounced Back Today
12:59pm, Wednesday, 20'th Aug 2025
Shares of Viking Therapeutics (VKTX 7.18%) rose by almost 10% at 11 a.m. ET today. This follows a significant fall the previous day on the release of its eagerly awaited top-line results from a phase
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
12:46pm, Wednesday, 20'th Aug 2025
VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
10:31am, Wednesday, 20'th Aug 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Viking Therapeutics: What's Happening With VKTX Stock?
09:50am, Wednesday, 20'th Aug 2025
Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over
Viking Therapeutics shares tumble after obesity drug trial disappoints
03:32am, Wednesday, 20'th Aug 2025
Shares in Viking Therapeutics (NASDAQ:VKTX) ended a bloody session 42% lower after the US biotech released trial data on its experimental obesity pill that underwhelmed investors. The phase two resu
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'
09:38pm, Tuesday, 19'th Aug 2025
Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as investors balked at tolerability concerns and dropout rates. The Phas
Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data
06:27pm, Tuesday, 19'th Aug 2025
Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
02:44pm, Tuesday, 19'th Aug 2025
Investors appear disappointed with Viking Therapeutics Inc.'s VKTX data from its Phase 2 trial of an obesity pill.
The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin
01:45pm, Tuesday, 19'th Aug 2025
Justin Zelin, BTIG senior biotech analyst, joins 'The Exchange' to discuss GLP-1's and the share decline for Viking Therapeutics and why he's still bullish the stock.
Viking Therapeutics plummets on new obesity drug data. Here's a breakdown
12:19pm, Tuesday, 19'th Aug 2025
CNBC's Angelica Peebles joins 'Money Movers' to discuss Viking Therapy shares plummeting on new obesity drug data.
Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
12:05pm, Tuesday, 19'th Aug 2025
Viking Therapeutics (VKTX) shares cratered nearly 45% Tuesday when the biopharma firm reported study of its experimental weight-loss pill raised concerns about side effects.
Viking Therapeutics shares plunge on weight loss trial tolerability concerns
12:04pm, Tuesday, 19'th Aug 2025
Viking Therapeutics (NASDAQ:VKTX) shares tumbled 43% on Tuesday following the release of data from its Phase 2a Venture Oral weight loss trial showing strong efficacy but raised tolerability concerns.
Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success
12:03pm, Tuesday, 19'th Aug 2025
Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite be
Why Viking Therapeutics Stock Crashed Today
11:16am, Tuesday, 19'th Aug 2025
Viking Therapeutics (VKTX -43.06%) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss p
